Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-09-22FDA Approved: AZACITIDINE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for Dr. Reddy's azacitidine (AZACITIDINE).
-
CLINICAL_TRIALS trial_result · 2020-09-21Clinical Trial Update: Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM [Phase 1, Phase 2]
Phase 1/2 clinical trial update for NiCord (umbilical cord blood-derived ex vivo expanded cells) in hematological malignancies, including AL…
-
FDA approval · 2020-09-16FDA Approved: DECITABINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Decitabine submitted by Sun Pharmaceutical Industries, Inc.
-
CLINICAL_TRIALS trial_result · 2020-09-10Clinical Trial Update: Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases [Phase 2]
Phase 2 trial evaluating myeloablative umbilical cord blood transplantation in various hematological diseases has completed with results pos…
-
CLINICAL_TRIALS trial_result · 2020-09-09Clinical Trial Update: Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy [Phase 2]
Phase 2 trial evaluating combined PD-1 inhibition and a DNA hypomethylating agent, with or without chemotherapy, in high-risk AML or elderly…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-09-09Clinical Trial Update: PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients [Phase 1, Phase 2]
A phase 1/2 clinical trial investigating autologous FMT to prevent dysbiosis-related complications in adults with acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2020-08-12Clinical Trial Update: IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT [Phase 1, Phase 2]
Clinical trial update on an IL-15 super agonist ALT-803 for relapse of hematologic malignancies after allogeneic stem cell transplant, compl…
-
CLINICAL_TRIALS trial_result · 2020-08-10Clinical Trial Update: Ponatinib for FLT3-ITD Acute Myelogenous Leukemia [Phase 1, Phase 2]
A clinical trial update on ponatinib for FLT3-ITD acute myeloid leukemia, spanning Phase 1 and Phase 2, with unclear status.
-
CLINICAL_TRIALS trial_result · 2020-08-07Clinical Trial Update: Bisantrene for Relapsed /Refractory AML [Phase 2]
Phase 2 clinical trial update for bisantrene in relapsed/refractory acute myeloid leukemia (AML), including patients with allogeneic stem ce…
-
FDA approval · 2020-08-06FDA Approved: AZACITIDINE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for azacitidine submitted by Fresenius Kabi USA, LLC.
-
CLINICAL_TRIALS trial_result · 2020-08-06Clinical Trial Update: Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML [Phase 2]
Phase 2 trial assessing midostaurin in acute myeloid leukemia with specific c-KIT or FLT3-ITD mutations; study status completed.
-
CLINICAL_TRIALS trial_result · 2020-07-31Clinical Trial Update: Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy [Phase 2]
Phase 2 clinical trial assessing early discharge and outpatient care for patients with myelodysplastic syndromes or acute myeloid leukemia p…
-
CLINICAL_TRIALS trial_result · 2020-07-30Clinical Trial Update: Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) [Phase 3]
Phase III trial comparing treosulfan-based conditioning to reduced-intensity conditioning in acute myeloid leukemia and myelodysplastic synd…
-
FDA approval · 2020-07-13FDA Approved: AZACITIDINE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for azacitidine submitted by BluePoint Laboratories, representing a modification to the existing NDA…
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 3]
Phase 3 study evaluating the combination of bortezomib and sorafenib tosylate in newly diagnosed acute myeloid leukemia has posted results. …
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 3]
Phase 3 trial evaluating bortezomib with sorafenib tosylate in newly diagnosed acute myeloid leukemia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-07-07Clinical Trial Update: DC Vaccination for Post-remission Therapy in AML [Phase 1, Phase 2]
Phase 1/2 clinical trial investigating dendritic cell vaccination as post-remission therapy in acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2020-06-26Clinical Trial Update: P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies [Phase 3]
Phase 3 trial of umbilical cord blood cells expanded with MPCs for transplantation in hematologic malignancies has completed.
-
FDA approval · 2020-06-26FDA Approved: CYTARABINE — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approval of Meitheal Pharmaceuticals' original ANDA for Cytarabine (cytarabine), a generic injectable anticancer agent.
-
CLINICAL_TRIALS trial_result · 2020-06-23Clinical Trial Update: A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). [Phase 1, Phase 2]
Phase Ib/IIb open-label study evaluating oral panobinostat with 5-azacitidine in adults with myelodysplastic syndromes, chronic myelomonocyt…
-
FDA approval · 2020-06-16FDA Approved: MYLOTARG — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for MYLOTARG (gemtuzumab ozogamicin) submitted by Wyeth Pharmaceuticals LLC, a subsidiary of Pfi…
-
CLINICAL_TRIALS trial_result · 2020-06-09Clinical Trial Update: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial update evaluating vosaroxin with infusional cytarabine for untreated acute myeloid leukemia; results have been posted…
-
FDA approval · 2020-06-08FDA Approved: AZACITIDINE — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved Hikma Pharmaceuticals USA Inc.'s generic azacitidine (AZACITIDINE) through an Original Application (ANDA 209337). This adds a g…
-
CLINICAL_TRIALS trial_result · 2020-06-04Clinical Trial Update: Protocol in Acute Myeloid Leukemia With FLT3-ITD [Phase 2]
A Phase 2 clinical trial update in acute myeloid leukemia with FLT3-ITD has been completed.
-
CLINICAL_TRIALS trial_result · 2020-06-02Clinical Trial Update: AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis [Phase 2]
Phase 2 trial of AZD1775 in advanced acute myeloid leukemia, myelodysplastic syndromes, and myelofibrosis was terminated with posted results…